Wholesale Acquisition Cost (WAC) Increase Report Data – Current Year

The interactive reports below include submitted WAC increase data from quarter 1 (Q1) 2021 through quarter 4 (Q4) 2021. These graphs display data that shows Median Cumulative WAC Percent Increase by WAC Price Category, Drug Source Type, or Both. The visualizations allow you to filter through the data by quarter.

Note: Reported increases that do not meet the statutory requirements for reporting and prescription drugs that do not meet the definition for reporting under the applicable California Regulations and Section 321(g) of Title 21 of the United States Code were not included in the visualizations. In calendar year 2021, 41 of 985 submitted reports did not meet the statutory requirements. For information on how HCAI created this product visit the CTRx program page.

Median Percent Increase – WAC Price Category

Key Findings

  • In 2021, the overall 3-year median WAC percent increase was 21.2%.
  • The smallest 3-year median WAC percent increase in 2021 (20.6%) occurred in Quarter 4 and was made on prescription drug products with a WAC over $10,000.
  • In Quarter 4 2021, the largest 3-year median WAC percent increase (30.1%) was made on prescription drug products with a WAC between $1,000 and $10,000.

Median Cumulative WAC Percent Increase by WAC Price Category (Q4 2021)

Median Percent Increase – Drug Source Type

Key Findings

  • In Quarter 4 2021, approximately 55% of reported WAC increases (41 reports out of 74 total reports) were made on Single Source Drugs.
  • In Quarter 4 2021, Non-innovator Multiple Source Drugs saw the largest 3-year median WAC percent increase (34.7%) across drug source types.

Median Cumulative WAC Percent Increase by Drug Source Type (Q4 2021)

Median Percent Increase – WAC Price Category & Drug Source Type

Key Findings

  • In Quarter 4 2021, Non-innovator Multiple Source Drugs with a WAC below $250 saw the largest 3-year median WAC percent increase (97.1%) across price categories and drug source types.
  • In Quarter 4 2021, the only reported WAC increases made on prescription drug products with a WAC greater than $10,000 were made on Single Source Drugs.
  • Approximately 41% of reported WAC increases made in Quarter 4 2021 (30 reports out of 74 total reports) were made on Single Source Drugs with a WAC between $250 and $10,000.

Median Cumulative WAC Percent Increase by WAC Price Category and Drug Source Type (Q4 2021)

Notes:

  • The 3-year median percent increase is based on submitted WAC increase data.
  • The dataset is subject to reporting. The dataset includes only complete reports submitted by manufacturers for WAC increases that were made in Q1 through Q4 2021, not including reports that do not meet the specified minimum thresholds for reporting.
  • Manufacturers can submit late reports; any Q1 through Q4 2021 WAC increase reports submitted after July 20, 2022, are not included in the data.
  • Manufacturers are required to provide the reason(s) for reported WAC increases unless the information is not in the public domain. Approximately 59% of Q1 2021, 43% of Q2 2021, 57% of Q3 2021, and 55% of Q4 2021 reports did not include any reason(s) for the reported WAC increases due to the information not already being in the public domain.

Data and Resources#

Additional Information#

Topic: Cost Transparency
Source: Cost Transparency – Prescription Drug (Rx) Costs
Citation: Department of Health Care Access and Information (HCAI), Prescription Drug Cost Transparency,  Current Year – 2021
Temporal Coverage: January to December 2021
Spatial/Geographic Coverage: Statewide
Frequency: Quarterly